Sunday, August 20, 2023 12:24:51 PM
Have Linda and Les done a good job? I would say yes they actually have done a super good job albeit alone almost without the help of any capable deputies. DI and the like are just window dressing. They just serve as a buffer or something non essential.
But because of the age of Linda and Les -- around 70 in average, they can do only that so it's no surprise to see delay, delay and delay, of course a significant part of that is due to the complex nature of seeking approvals of DCVax-L by multiple RAs from a trial which is unprecedented in many ways. Nonetheless it will be definitely approved by the multiple RAs due to its results are "both statistically significant and clinically meaningful" -- conclusion from the high-impact JAMA Oncology landmark paper.
During the long delayed process, the vast majority of retail investors who have been repeatedly recognized as backbone of the support to the company by Linda have suffered emotionally and monetarily due to in a significant part, heavy dilution.
The management, mainly Linda and Les can and should show that we, the vast numbers of retail investors and the management are truly in the same boat; we shall suffer, endure, flourish and prosper together. The management can at least do the following:
1) Buy in open market, if having not yet scheduled, do now;
2) Rearrange the pay package. Cut substantially the future milestone payments of both shares and warrants; Compared to injecting new valor and confidence to the investment community by doing so, I don't see any difference of rewarding themselves with 30 millions or 15 millions of warrants (just example, not the real numbers); and
3) Throw off the shackles of the myth that FDA is a totally corrupted monster which has been better not poked or "offended" in any way so that NWBio shall continually operate in a stealthy mode behind the scene. Well the publication of the JAMA Oncology paper has changed that, or everything in effect. Nothing should we fear for now, and Linda and the gang shall embark on a new journey so that we won't be so passive anymore and instead we should take a more proactive role, fanning out people to promote the company as much as possible. Truth flourishes in light, not darkness!
When we remember the conclusion from the high impact JAMA Oncology paper re P3 DCVax-L trial for GBM: the results are "both statistically significant and clinically meaningful," nothing and nobody shall we fear! We should be in the teens when clouds are clear and dusts are settled. In the meanwhile, get dry powder ready to chase the shares until the 7 accused MMs and their complicit short can no longer manipulate the market.
But because of the age of Linda and Les -- around 70 in average, they can do only that so it's no surprise to see delay, delay and delay, of course a significant part of that is due to the complex nature of seeking approvals of DCVax-L by multiple RAs from a trial which is unprecedented in many ways. Nonetheless it will be definitely approved by the multiple RAs due to its results are "both statistically significant and clinically meaningful" -- conclusion from the high-impact JAMA Oncology landmark paper.
During the long delayed process, the vast majority of retail investors who have been repeatedly recognized as backbone of the support to the company by Linda have suffered emotionally and monetarily due to in a significant part, heavy dilution.
The management, mainly Linda and Les can and should show that we, the vast numbers of retail investors and the management are truly in the same boat; we shall suffer, endure, flourish and prosper together. The management can at least do the following:
1) Buy in open market, if having not yet scheduled, do now;
2) Rearrange the pay package. Cut substantially the future milestone payments of both shares and warrants; Compared to injecting new valor and confidence to the investment community by doing so, I don't see any difference of rewarding themselves with 30 millions or 15 millions of warrants (just example, not the real numbers); and
3) Throw off the shackles of the myth that FDA is a totally corrupted monster which has been better not poked or "offended" in any way so that NWBio shall continually operate in a stealthy mode behind the scene. Well the publication of the JAMA Oncology paper has changed that, or everything in effect. Nothing should we fear for now, and Linda and the gang shall embark on a new journey so that we won't be so passive anymore and instead we should take a more proactive role, fanning out people to promote the company as much as possible. Truth flourishes in light, not darkness!
When we remember the conclusion from the high impact JAMA Oncology paper re P3 DCVax-L trial for GBM: the results are "both statistically significant and clinically meaningful," nothing and nobody shall we fear! We should be in the teens when clouds are clear and dusts are settled. In the meanwhile, get dry powder ready to chase the shares until the 7 accused MMs and their complicit short can no longer manipulate the market.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
